Real-world disease outcomes and safety in patients with mild to moderate COVID-19 treatedwith JT001
Not Provided
Drug: JT001
oral administration
Other Name: DeuremidevirHydrobromideTablets
Inclusion Criteria:
1. Age ≥18 years old.
2. The novel coronavirus infection (COVID-19) meets at least one of the following five
criteria:
1) Diagnosis of novel coronavirus infection; 2) Diagnosed with novel coronavirus
pneumonia; 3) The novel coronavirus nucleic acid test is positive; 4) Test positive
for novel coronavirus antigen; 5) Culture positive for novel coronavirus.
3. Patients who have not developed severe COVID-19 or died within 28 days of COVID-19
diagnosis, or who have developed severe COVID-19 or died within 28 days of COVID-19
diagnosis, were treated with deuterimodivir hydrobromide tablets or were not treated
with anti-novel coronavirus before disease progression.
Exclusion Criteria:
· Patients who have not developed severe COVID-19 or died within 28 days of COVID-19
diagnosis, or those who have developed severe COVID-19 or died within 28 days of COVID-19
diagnosis, received the following anti-novel coronavirus treatments before disease
progression, including: Nematavir tablet/Ritonavir tablet, Azvudine tablet, Monoravir
capsule, Zenotavir tablet/Ritonavir tablet, Leritvir tablet, Ambavirzumab/Romisivir
injection, human immunoglobulin for COVID-19 or convalescent plasma for COVID-19
survivors.
Peking university first hospital
Beijing, Beijing, China
Shanghai Fourth People's Hospital
Shanghai, Shanghai, China
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai, China
Gongli Hospital, Pudong New Area, Shanghai
Shanghai, Shanghai, China
Central Hospital of Minhang District, Shanghai
Shanghai, Shanghai, China
Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center
Shanghai, Shanghai, China
Not Provided